The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.
IMS Health Top 20 pharmaceutical companies 2009
Home/Pharma News | Posted 23/04/2010 0 Post your comment
The data below does not take into account the large acquisitions by Pfizer and Merck, of Wyeth and Schering-Plough respectively, which were completed after September 2009.
Company Sales | (billion US$) | % change |
1. Pfizer | 41.7 | (0.8) |
2. Novartis | 36.7 | 7.0 |
3. Sanofi-aventis | 35.1 | 3.3 |
4. GlaxoSmithKline | 34.3 | (3.4) |
5. AstraZeneca | 33.2 | 7.8 |
6. Roche | 31.3 | 8.6 |
7. Johnson & Johnson | 26.9 | (6.6) |
8. Merck & Co | 25.0 | (4.1) |
9. Eli Lilly | 19.6 | 8.3 |
10. Abbott | 19.4 | 5.5 |
11. Teva | 15.7 | 12.3 |
12. Bayer | 15.4 | 3.9 |
13. Wyeth | 14.8 | (2.3) |
14. Amgen | 14.8 | (3.1) |
15. Boehringer Ingelheim | 14.6 | 10.4 |
16. Takeda | 14.4 | 2.1 |
17. Bristol-Myers | 14.2 | 5.8 |
18. Schering-Plough | 13.1 | 4..3 |
19. Daiichi Sankyo | 8.5 | 3.1 |
20. Novo Nordisk | 8.2 | 11.6 |
References:
IMS Health
FACTBOX-The 20 largest pharmaceutical companies. Reuters. 2010 March 26.
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Policies & Legislation
Regulatory Certainty Strategy for biosimilars launched in Mexico
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Related content
mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta
Home/Pharma News Posted 09/04/2024
Biosimilars lawsuits and settlement updates for Regeneron and Alvotech
Home/Pharma News Posted 22/03/2024
Most viewed articles
Comments (0)
Post your comment